179 related articles for article (PubMed ID: 20510070)
1. [How to optimize the clinical therapeutic protocol for triple-positive breast cancer].
Wang N; Wang YJ
Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):241-3. PubMed ID: 20510070
[No Abstract] [Full Text] [Related]
2. [Molecular subtypes and individualized treatment of breast cancer].
Xu BH; Zhang P
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):641-4. PubMed ID: 21122374
[No Abstract] [Full Text] [Related]
3. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
4. Triple-negative breast cancer.
Oncology (Williston Park); 2010 Oct; 24(10 Suppl):40a. PubMed ID: 21275325
[No Abstract] [Full Text] [Related]
5. [Changing behavior of estrogen and progesterone receptors with metastasis or recurrence of breast cancer].
Morimoto K; Koh M; Yamamoto A; Tamura K; Yamamoto K; Yamamoto K; Suehiro S
Gan To Kagaku Ryoho; 2006 Jul; 33(7):925-9. PubMed ID: 16835481
[TBL] [Abstract][Full Text] [Related]
6. Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related.
Neven P; Pochet N; Drijkoningen M; Amant F; De Smet F; Paridaens R; Christiaens MR; Vergote I
J Clin Oncol; 2006 Jun; 24(16):2595; author reply 2595-7. PubMed ID: 16735717
[No Abstract] [Full Text] [Related]
7. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.
Roukos DH
J Clin Oncol; 2010 Jun; 28(17):e279-80; author reply e282-3. PubMed ID: 20406920
[No Abstract] [Full Text] [Related]
8. Molecular subtype shift in breast cancer upon trastuzumab treatment: a case report.
Āboliņš A; Vanags A; Trofimovičs G; Miklaševičs E; Gardovskis J; Štrumfa I
Pol J Pathol; 2011; 62(1):65-8. PubMed ID: 21574108
[TBL] [Abstract][Full Text] [Related]
9. New approaches for triple-negative breast cancer.
Oncology (Williston Park); 2012 Oct; 26(10):916, 931, 935. PubMed ID: 23175999
[No Abstract] [Full Text] [Related]
10. From the guest editor: Triple-negative breast cancer.
Hudis CA
Cancer J; 2010; 16(1):10-1. PubMed ID: 20164684
[No Abstract] [Full Text] [Related]
11. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.
Muss HB; Bunn JY; Crocker A; Plaut K; Koh J; Heintz N; Rincon M; Weaver DL; Tam D; Beatty B; Kaufman P; Donovan M; Verbel D; Weiss L
Breast J; 2007; 13(4):337-45. PubMed ID: 17593037
[TBL] [Abstract][Full Text] [Related]
12. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
Glück S; Arteaga CL; Osborne CK
Clin Cancer Res; 2011 Sep; 17(17):5559-61. PubMed ID: 21764887
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen benefits and CYP2D6 testing in women with hormone receptor-positive breast cancer.
Kaplan M; Mahon SM
Clin J Oncol Nurs; 2013 Apr; 17(2):174-9. PubMed ID: 23538253
[TBL] [Abstract][Full Text] [Related]
14. Triple-negative breast cancer and brain metastases.
Sait B; Cinar E; Altundag K
Clin Oncol (R Coll Radiol); 2010 Feb; 22(1):84. PubMed ID: 19751969
[No Abstract] [Full Text] [Related]
15. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy.
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1095-101. PubMed ID: 20638197
[TBL] [Abstract][Full Text] [Related]
16. Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?
Arslan C; Isik M; Guler G; Kulac I; Solak M; Turker B; Ozisik Y; Altundag K
Am Surg; 2012 Sep; 78(9):992-9. PubMed ID: 22964210
[TBL] [Abstract][Full Text] [Related]
17. Estrogen and progesterone receptors in breast cancer.
Ma CX
Clin Adv Hematol Oncol; 2011 May; 9(5):385-6. PubMed ID: 21685867
[No Abstract] [Full Text] [Related]
18. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers.
Nahta R; O'Regan RM
Breast Cancer Res Treat; 2012 Aug; 135(1):39-48. PubMed ID: 22527112
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biological characteristics of breast cancer.
Kocic B; Filipovic S; Petrovic B; Mijalkovic D; Rancic N; Poultsidi A
J BUON; 2010; 15(4):660-7. PubMed ID: 21229626
[TBL] [Abstract][Full Text] [Related]
20. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo.
Schubert A; Hawighorst T; Emons G; Gründker C
Breast Cancer Res Treat; 2011 Dec; 130(3):783-90. PubMed ID: 21279682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
